Company

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. We are currently developing a PET-imaging diagnostic for liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for advanced CMS4 colon cancer. Our platform and drug development engine is based on proprietary PDGF-ß-receptor medium affinity binding bicyclic peptides and PDGF-ß-receptor high affinity VHH nanobodies.

Read more

Target

Fibrotic tissue, as present in liver fibrosis and in mesenchymal type colon cancer stroma, is characterized by abundant myofibroblast-specific overexpression of the PDGF-ß-receptor. This over-expressed receptor allows myofibroblast-specific targeting and delivery of antifibrotic drugs, thereby leaving healthy tissues unaffected. After binding of BiOrion’s peptide-conjugate to the receptor, the complex is internalized and accumulated rapidly and, dependent on the payload, can exert its intracellular effect.

Read more

Pipeline

BiOrion runs three active development programs. Hepatoscan®, is a PET imaging diagnostic to identify and stratify patients with hepatic fibrosis. In the imaging diagnostic Oncoloscan®, the PET radionuclide 68Gallium is conjugated to the PDGF-ß-receptor binding VHH nanobody whereas in Oncoluthera ® the PET radionuclide 177Lutetium is conjugated to this VHH nanobody. Both are developed for patients suffering from advanced CMS4 colorectal cancer. Fibroferon®, finaly, is PDGF-ß-receptor targeted C-terminal signaling domain of interferon gamma. Fibroferon® is primarily developed for targeted antifibrotic therapy of patients suffering from hepatic fibrosis.

Read more

Selective Targeting of Fibrotic stroma

allowing precise PET radio-imaging and radiotherapy of mesenchymal type colon cancer

 News

More News >>

 Events

no event

 Partners